39 related articles for article (PubMed ID: 38443692)
1. Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors.
Hummel L; Ameri M; Alqahtani S; Sadighi Z; Al-Zubidi N
Curr Oncol; 2024 May; 31(5):2644-2649. PubMed ID: 38785480
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas.
Jakacki RI; Dombi E; Steinberg SM; Goldman S; Kieran MW; Ullrich NJ; Pollack IF; Goodwin A; Manley PE; Fangusaro J; Allen R; Widemann BC
Neuro Oncol; 2017 Feb; 19(2):289-297. PubMed ID: 27510726
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management.
Borgia P; Piccolo G; Santangelo A; Chelleri C; Viglizzo G; Occella C; Minetti C; Striano P; Diana MC
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542016
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study.
Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A
Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023
[TBL] [Abstract][Full Text] [Related]
5. Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children.
Dávila Osorio VL; Vicente MA; Baselga E; Salvador H; Cruz O; Prat C
Pediatr Dermatol; 2021 Mar; 38(2):420-423. PubMed ID: 33368596
[TBL] [Abstract][Full Text] [Related]
6. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.
Ibraheim MK; Lo J; Gupta R; Parseghian C; Patel AB
Support Care Cancer; 2022 Oct; 30(10):8051-8058. PubMed ID: 35771289
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank PMK; Gross AM; Akshintala S; Blakeley JO; Bollag G; Cannon A; Dombi E; Fangusaro J; Gelb BD; Hargrave D; Kim A; Klesse LJ; Loh M; Martin S; Moertel C; Packer R; Payne JM; Rauen KA; Rios JJ; Robison N; Schorry EK; Shannon K; Stevenson DA; Stieglitz E; Ullrich NJ; Walsh KS; Weiss BD; Wolters PL; Yohay K; Yohe ME; Widemann BC; Fisher MJ
Neuro Oncol; 2022 Nov; 24(11):1845-1856. PubMed ID: 35788692
[TBL] [Abstract][Full Text] [Related]
9. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
10. Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.
Brown R
Curr Oncol Rep; 2023 Dec; 25(12):1409-1417. PubMed ID: 37906356
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]